Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sunitinib therapy for melanoma patients with KIT mutations.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2012

Minor David R, Kashani-Sabet Mohammed, Garrido Maria, O'Day Steven J, Hamid Omid, Bastian Boris C

Abstract excerpt

PURPOSE: Recent studies have shown activating KIT mutations in melanoma originating from mucosa, acral, or cumulative sun-damaged skin sites. We aimed to assess the predictive role of KIT mutation, amplification, or overexpression for response to treatment with the kinase inhibitor sunitinib. EXPERIMENTAL DESIGN: Tumor tissues from 90 patients with stage III or IV acral, mucosal, or cumulative sun-damaged skin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Melanoma

Share to Proto-Oncogene Proteins c-kit

Share to Pyrroles

Share to Sunitinib

Share to Survival Analysis

Source

Identifiers

PMID: 22261812
DOI: 10.1158/1078-0432.CCR-11-1987

Genes

KIT
NRAS
BRAF
GNAQ

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sunitinib therapy for melanoma patients with KIT mutations.PMID 22261812Read ↗

KIT as a therapeutic target in metastatic melanoma.Semantic proximity Read ↗

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.Semantic proximity Read ↗

c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.Semantic proximity Read ↗

Somatic Activation of KIT in Distinct Subtypes of MelanomaSemantic proximity Read ↗

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.Semantic proximity Read ↗

Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.Semantic proximity Read ↗

KIT and Melanoma: Biological Insights and Clinical Implications.Semantic proximity Read ↗

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.Semantic proximity Read ↗

The clinical significance of KIT mutations in melanoma: a meta-analysis.Semantic proximity Read ↗

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.Semantic proximity Read ↗

Another Option in Our KIT of Effective Therapies for Advanced MelanomaSemantic proximity Read ↗

Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.